Key result
Rare splice-disrupting variants were identified in 10.3% of patients with inherited heart disease or sudden unexplained death, with a significant excess burden in genes including PKP2, FLNC, TTN, MYBPC3, MYH7, and KCNQ1 compared to population controls.
Why the study?
The burden of splice-disrupting variants in definitively associated inherited heart disease genes and the feasibility of amplifying these genes from blood RNA for functional confirmation were incompletely understood.
Does burden testing and blood RNA analysis of splice-disrupting variants improve variant pathogenicity classification in patients with inherited heart disease and sudden unexplained death?
Case-Control (n=1,242)
Yes
Does burden testing and blood RNA analysis of splice-disrupting variants improve variant pathogenicity classification in patients with inherited heart disease and sudden unexplained death?
Splice-disrupting variants are a significant cause of inherited heart disease, and blood RNA analysis can effectively confirm splicing outcomes to reclassify variants of uncertain significance.
Supports RNA analysis for reclassifying splice variants in inherited heart disease; leaves open prospective validation before changing practice.
There is an incomplete understanding of the burden of splice-disrupting variants in definitively associated inherited heart disease genes and whether these genes can amplify from blood RNA to support functional confirmation of splicing outcomes. We performed burden testing of rare splice-disrupting variants in people with inherited heart disease and sudden unexplained death compared to 125,748 population controls. ClinGen definitively disease-associated inherited heart disease genes were amplified using RNA extracted from fresh blood, derived cardiomyocytes, and myectomy tissue. Variants were functionally assessed and classified for pathogenicity. We found 88 in silico-predicted splice-disrupting variants in 128 out of 1242 (10.3%) unrelated participants. There was an excess burden of splice-disrupting variants in PKP2 (5.9%), FLNC (2.7%), TTN (2.8%), MYBPC3 (8.2%) and MYH7 (1.3%), in distinct cardiomyopathy subtypes, and KCNQ1 (3.6%) in long QT syndrome. Blood RNA supported the amplification of 21 out of 31 definitive disease-associated inherited heart disease genes. Our functional studies confirmed altered splicing in six variants. Eleven variants of uncertain significance were reclassified as likely pathogenic based on functional studies and six were used for cascade genetic testing in 12 family members. Our study highlights that splice-disrupting variants are a significant cause of inherited heart disease, and that analysis of blood RNA confirms splicing outcomes and supports variant pathogenicity classification.
No takes yet. Share an insight, caveat, or question.
Singer et al. (2023) conducted a case-control in Inherited heart disease and sudden unexplained death (n=1,242). Rare splice-disrupting variants vs. Population controls (gnomAD) was evaluated on Burden of rare in silico-predicted splice-disrupting variants (p=<0.001). Rare splice-disrupting variants were identified in 10.3% of patients with inherited heart disease or sudden unexplained death, with a significant excess burden in genes including PKP2, FLNC, TTN, MYBPC3, MYH7, and KCNQ1 compared to population controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: